Two Sigma Securities’s Processa Pharmaceuticals PCSA Stock Holding History

Two Sigma Securities’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,450	Closed	-$6.96K	–	1880
2025 Q3	$6.96K	Buy	+1,450	New	+$7.66K	﹤0.01%	1241
2023 Q3	–	Sell	-21	Closed	-$5.32K	–	3338
2023 Q2	$5.32K	Sell	21 -104	-83%	-$30.7K	﹤0.01%	2664
2023 Q1	$31.3K	Buy	+125	New	+$50.3K	﹤0.01%	2317

Other funds holding PCSA

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Two Sigma Securities's PCSA Position: Q4 2025 in Review

Two Sigma Securities sold out of Processa Pharmaceuticals (PCSA) in Q4 2025, closing a stake of 1,450 shares — an estimated $6.96K sold.

Two Sigma Securities first reported a position in PCSA in Q1 2023 and held it in 3 quarters. The position peaked at $31.3K in Q1 2023. 10 funds tracked by Wall St. Rank hold PCSA as of Q4 2025.

Two Sigma Securities reported no remaining Processa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Two Sigma Securities sold 1,450 Processa Pharmaceuticals shares in Q4 2025, an estimated $6.96K.
Two Sigma Securities first reported a position in Processa Pharmaceuticals in Q1 2023 and held it in 3 quarters.
Two Sigma Securities's Processa Pharmaceuticals position peaked at $31.3K in Q1 2023.
10 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.